Dear Friend of DKT,
June 24th marks one year since the Supreme Court of the United States overturned Roe v. Wade, the landmark 1973 decision that legalized abortion in the United States. This past year has been a challenging one for our domestic affiliate, carafem, with legal questions and battles still raging around the use of mifepristone for medical abortion (MA). Despite the barriers faced, carafem continues to innovate its care and serve individuals in 17 states via telehealth services. Around the world, DKT also is expanding access to abortion products and services. DKT remains steadfast in our support of a woman’s right to determine her reproductive destiny.
The second quarter of 2023 was significant for new product launches and expansion, as we are proud to share that DKT MENA logged its first, large sales orders in Iraq. DKT’s West Africa program also launched injectable contraception in Mali and DKT WomanCare continued pushing forward with training and sales in Uzbekistan (IUDs), Kyrgyzstan (Levoplant), and Madagascar (EC pills).
In addition to internal achievements, DKT also continues contributing valuable research to the larger SRH field. DKT WomanCare’s Commercial Director, True Overholt was published in the International Journal of Gynecology & Obstetrics for his work in partnership with Ipas and a consortium of researchers on a multi-national study on the use and re-use of MVA aspirators in abortion and post-abortion care.
Finally, June has been a joyous month for the LGBTQIA+ community and our teams around the world who were busy with outreach programming related to Pride Month in Mexico, Myanmar, Brazil and Vietnam (just to name a few). One of DKT’s core values is “fun” and our marketing teams took things (as always) to the next level.
As always, we appreciate and thank you for your continued support.
Cheers,
Christopher Purdy
|